Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival.
about
Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cellsThe cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial designTwo 4N cell-cycle arrests contribute to cisplatin-resistanceChronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancerAtaxia telangiectasia mutated- and Rad3-related kinase drives both the early and the late DNA-damage response to the monofunctional antitumour alkylator S23906.Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.RAD18-mediated ubiquitination of PCNA activates the Fanconi anemia DNA repair network.Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970Replication stress by Py-Im polyamides induces a non-canonical ATR-dependent checkpoint response.In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.Antitumoral materials with regenerative function obtained using a layer-by-layer techniqueParaspeckle protein 1 (PSPC1) is involved in the cisplatin induced DNA damage response--role in G1/S checkpoint.p22phox confers resistance to cisplatin, by blocking its entry into the nucleus.Evaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype.Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.Synthesis, characterization, and evaluation of cis-diphenyl pyridineamine platinum(II) complexes as potential anti-breast cancer agentsThe Fanconi Anemia Pathway Maintains Genome Stability by Coordinating Replication and Transcription.Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.Genomically Incorporated 5-Fluorouracil that Escapes UNG-Initiated Base Excision Repair Blocks DNA Replication and Activates Homologous RecombinationChemotherapy induced DNA damage response: convergence of drugs and pathwaysATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines.Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies.Signalling mechanisms involved in renal pathological changes during cisplatin-induced nephropathy.Cisplatin-induced renal toxicity magn…ified: role of magnesium deficiency in AKI onset.Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.Glycogen Synthase Kinase 3 (GSK-3)-mediated Phosphorylation of Uracil N-Glycosylase 2 (UNG2) Facilitates the Repair of Floxuridine-induced DNA Lesions and Promotes Cell Survival.Targeting the ATR-CHK1 Axis in Cancer TherapyThe Phytoestrogen Genistein Affects Breast Cancer Cells Treatment Depending on the ERα/ERβ Ratio.USP7 is essential for maintaining Rad18 stability and DNA damage tolerance.Prospects for the Use of ATR Inhibitors to Treat Cancer.Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.The ruthenium complexes cis-(dichloro)tetramineruthenium(III) chloride and cis-tetraammine(oxalato)ruthenium(III) dithionate overcome resistance inducing apoptosis on human lung carcinoma cells (A549).Microbiota: a key orchestrator of cancer therapy.Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.
P2860
Q26851196-B1CF441F-44C3-4123-B33A-17C23AB480B5Q28289090-56E83BBE-0DE4-4181-8545-07BA39C4576EQ28485896-454E4FE5-85E9-466A-90B9-DB12BA0F4BB7Q33788519-A43889E3-0BC8-4C4D-8D5B-34FCC3236862Q33864110-58213A41-760F-4545-9345-7D9A41CF1F61Q34110442-08165934-2623-4803-BA04-F91438BA8BB7Q34218864-CC8AA087-3BC2-44FB-8DBA-C52C3C13FD8AQ34221860-0830528F-CF09-476F-BC82-5A4A12192436Q34313126-2BDE6426-E9CE-43B3-B20A-DD3698872885Q34334533-885A3117-4DB4-4C58-B74B-EA1A2219270FQ35078304-7626F1F4-F0D6-47CB-ABF3-7B02A5F49D6EQ35112912-A393647E-B6E0-4C56-ABCD-F879FADB0760Q35161657-E83F3DC8-B4A8-4B4B-A27B-8FF00F63F183Q35167161-706D5C6D-FDE8-4A1F-9BD2-3D45F77563FDQ35551953-C4AF6992-9BD0-4E6C-BCE2-8F1586689D59Q36009717-773EC69F-FC08-406A-B81C-564FDFCB5892Q36119145-8A9DBD8B-2E92-48C2-A022-E1F774A0F78EQ36129322-45578F19-FDAC-4A66-9949-70B4CD822F1EQ36270717-0F1C6D6D-3FD0-40DE-9F00-B0CBD6DE3EEAQ36278226-3628165C-3F1F-4A80-80DB-FB997AE1759FQ36294441-FA5A9D42-291D-4ADD-AD8C-055C48677897Q36432422-69151520-21DC-4074-ABF4-EAE7AE557FF8Q36901484-3C6CE58D-4285-424F-A14D-0A4A1424EB25Q36941455-79EF207C-B3FA-4810-A286-8D0AA1260694Q37392963-5610EA37-DA4F-4D69-8BE9-65C05F13BE32Q37457809-0F563604-B281-4674-A21A-40B9B8BE2EBEQ37691597-1A59134A-815C-42A2-B421-9189B7A21C51Q37729428-5E22628C-8C1C-449B-83E9-45B8BA62104BQ38127618-4D38DEC7-02B4-440B-B912-CEE030BE90FCQ38618836-7E6969FC-3AB3-4400-8E05-F2353B284494Q38660811-585DD0FA-4019-45E2-BDFA-A5EAAFC5DE25Q38729647-65EA4358-5B5C-4667-B4C4-EB32E330C25FQ38817102-2ACB8DBA-BD94-46BE-B7F4-84E2E3D2BB1FQ38861044-AA99D149-65CE-4A7D-9B9D-79A139FDE6BEQ38876635-F2500722-CB1D-414B-BCE4-84FB9BED848CQ38974279-B15BBF68-B5AF-46AE-AA15-75511C8ACFDAQ38983310-35C524BD-7EE6-4AB7-AF9B-CEA02BFB665FQ39000197-567C96CF-A170-4DC1-B926-91D9D283E8DFQ39183428-24A9B0B2-B7D7-4074-98E0-F41FE2A90024Q39301264-CDEFE6C7-8E32-4D63-9CCD-B3B3CB3A5C06
P2860
Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Cisplatin-induced DNA damage a ...... ly affect tumor cell survival.
@en
Cisplatin-induced DNA damage a ...... ly affect tumor cell survival.
@nl
type
label
Cisplatin-induced DNA damage a ...... ly affect tumor cell survival.
@en
Cisplatin-induced DNA damage a ...... ly affect tumor cell survival.
@nl
prefLabel
Cisplatin-induced DNA damage a ...... ly affect tumor cell survival.
@en
Cisplatin-induced DNA damage a ...... ly affect tumor cell survival.
@nl
P2860
P356
P1476
Cisplatin-induced DNA damage a ...... ly affect tumor cell survival.
@en
P2093
Jill M Wagner
Larry M Karnitz
P2860
P304
P356
10.1124/MOL.109.055178
P577
2009-04-29T00:00:00Z